Benedetta Pellegrino, Resident in Medical Oncology at the University Hospital of Parma, shared on X:
“Discover our latest study on the validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1 in breast and ovarian cancer! ”
Read further.
Source: Benedetta Pellegrino/X